Pathfinder Cell Therapy (PFND) 10-K/A 27 May 14 2013 FY Annual report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'Pathfinder Cell Therapy, Inc.	'	'
Entity Central Index Key	'0000889428	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Well-Known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$6,332,000
Entity Common Stock, Shares Outstanding	'	667,160,870	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash	$44	$9
Accounts receivable	'	28
Inventory, net of reserve of $13, and $0, respectively	'	33
Prepaid expenses	75	78
Total current assets	119	148
Intangible, net of accumulated amortization	36	208
TOTAL	155	356
Current liabilities:	'	'
Accounts payable	190	76
Accrued expenses (including related party amount of $312, and $370, respectively)	527	630
Current portion of long term payable	'	15
Insurance note payable	45	45
Note payable - Clubb Capital	244	244
Convertible notes payable (including related party amount of $2,135 and $700, respectively)	3,700	1,965
Total current liabilities	4,706	2,975
Long term payable - net of current portion	'	232
Commitments and other matters (Note H)	'	'
Capital deficit:	'	'
Preferred stock, $.01 par value; shares authorized - 5,000; issued and outstanding - none	'	'
Common stock, $.001 par value; shares authorized - 1,000,000 issued and outstanding - 667,162 and 667,162 at December 31, 2013 and December 31, 2012, respectively	667	667
Additional paid-in capital	11,828	11,823
Accumulated deficit	-17,046	-15,341
Total capital deficit	-4,551	-2,851
TOTAL	$155	$356

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Balance Sheet [Abstract]	'	'
Inventory reserve	$13	$0
Related party amount of accrued expenses	312	370
Related party of convertible notes payable	$2,135	$700
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	1,000,000	1,000,000
Common stock, shares issued	667,162	667,162
Common stock, shares outstanding	667,162	667,162

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		62 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenue	'	'	'
Product sales	$54	$114	$241
Revenue	54	114	241
Cost of goods sold	37	50	113
Gross profit	17	64	128
Operating expenses:	'	'	'
Research and development	672	1,084	4,116
General and administrative	921	1,015	4,629
Sales and marketing	23	25	78
Impairment of intangible assets	161	'	8,288
Operating expenses	1,777	2,124	17,111
Loss from operations before other income / (expense)	-1,760	-2,060	-16,983
Other income/(expense):	'	'	'
Interest (expense), net	-195	-96	-437
Reversal of a liability	250	'	374
Other income/(expense)	55	-96	-63
Net loss	($1,705)	($2,156)	($17,046)
Net loss per common share-basic and diluted	$0	$0	'
Weighted average shares outstanding	667,162	667,162	'

Consolidated_Statements_of_Cha

Consolidated Statements of Changes In Stockholders Equity (USD $)		Total	Common Stock	Additional Paid In Capital	Accumulated Loss
In Thousands, except Share data
Beginning Balance, shares at Nov. 04, 2008		'	'	'	'
Cash Contributions	[1]	$0	$332	($332)	'
Cash Contributions, shares	[1]	'	332,050	'	'
Net Loss for Period		-32	'	'	-32
Balance at Dec. 31, 2008		-32	332	-332	-32
Balance, shares at Dec. 31, 2008		'	332,050	'	'
Cash Contributions		430	'	430	'
Equity Issued for License*	[1]	11	126	-115	'
Equity Issued for License*, shares	[1]	'	125,950	'	'
Net Loss for Period		-547	'	'	-547
Balance at Dec. 31, 2009		-138	458	-17	-579
Balance, shares at Dec. 31, 2009		'	458,000	'	'
Cash Contributions		307	'	307	'
Net Loss for Period		-1,294	'	'	-1,294
Balance at Dec. 31, 2010		-1,125	458	290	-1,873
Beginning Balance, shares at Dec. 31, 2010		'	458,000	'	'
Opening balance restatement for MGH license		-42	'	'	-42
Issuance of shares in Merger transaction - September 2, 2011		6,020	114	5,906	'
Issuance of shares in Merger transaction - September 2, 2011, shares		'	114,500	'	'
Issuance of shares in a private placement and conversion of notes payable - September 2, 2011 at $0.05 per shares, net of placement costs of $575		3,909	90	3,819	'
Issuance of shares in a private placement and conversion of notes payable - September 2, 2011 at $0.05 per shares, net of placement costs of $575, shares		'	89,662	'	'
Issuance of warrants to placement agent		237	'	237	'
Issuance of shares in settlement of Yissum liability		350	5	345	'
Issuance of shares in settlement of Yissum liability, shares		'	5,000	'	'
Shareholder contribution -3% merger fee due to MGH		687	'	687	'
Stock-based Compensation		527	'	527	'
Net Loss for Period		-11,270	'	'	-11,270
Balance at Dec. 31, 2011		-707	667	11,811	-13,185
Balance, shares at Dec. 31, 2011		'	667,162	'	'
Stock-based Compensation		12	'	12	'
Net Loss for Period		-2,156	'	'	-2,156
Balance at Dec. 31, 2012		-2,851	667	11,823	-15,341
Balance, shares at Dec. 31, 2012		'	667,162	'	'
Stock-based Compensation		5	'	5	'
Net Loss for Period		-1,705	'	'	-1,705
Balance at Dec. 31, 2013		($4,551)	$667	$11,828	($17,046)
Balance, shares at Dec. 31, 2013		'	667,162	'	'
[1]	Share amounts, common stock and additional paid-in capital amounts were restated using the exchange ratio of the Merger to reflect the legal structure of legal acquirer (Note A)

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes In Stockholders Equity (Parenthetical) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2011
Statements Of Changes In Stockholders Equity [Abstract]	'
Stock issuance date of merger transaction and of private placement and conversion of notes payable	2-Sep-11
Issuance of shares, price per share	$0.05
Issuance of shares, placement costs	$575
Merger fee due to MGH	3.00%

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		62 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flows from operating activities:	'	'	'
Net loss	($1,705)	($2,156)	($17,046)
Adjustments to reconcile net loss to Net cash used in operating activities:	'	'	'
Depreciation and amortization	11	20	82
Stock based compensation relating to options	5	12	544
Shareholder contribution -3% merger fee due to MGH	'	'	687
Goodwill/intangible impairment loss	161	'	8,288
Reversal of liability	-250	'	-374
Accretion of long term liability	3	17	20
Changes in operating assets and liabilities:	'	'	'
Decrease in accounts receivable	28	26	101
Decrease in inventory	33	18	76
Decrease in prepaid expenses	102	136	282
Increase (decrease) in accounts payable	114	-167	187
(Decrease) increase in accrued expenses	-103	70	38
Net cash used in operating activities	-1,601	-2,024	-7,115
Cash flows from investing activities:	'	'	'
Acquisition of licenses	'	'	-90
Payments for notes receivable	'	'	-1,173
Cash acquired from merger	'	'	14
Net cash used in investing activities	0	0	-1,249
Cash flows from financing activities:	'	'	'
Net proceeds from the issuance of common stock	'	'	1,283
Payments of insurance note payable	-99	-128	-289
Proceeds from convertible notes payable	1,735	1,965	6,677
Contributions from Pathfinder, LLC members	'	'	737
Net cash provided by financing activities	1,636	1,837	8,408
Net (decrease) increase in cash	35	-187	44
Cash at beginning of period	9	196	'
Cash at end of period	44	9	44
Supplementary disclosure of non-cash investing and financing activities:	'	'	'
Members' equity issued for license	'	'	11
Notes receivable and payable through intermediary entity	'	'	130
Long term payable for license	'	'	177
Financing of placement agent commission through notes payable	'	'	244
Financing of insurance premiums through notes payable	99	99	334
Common stock issued in settlement of Yissum liability	'	'	350
Conversion of notes into common stock	'	'	3,107
Details of merger with SyntheMed:	'	'	'
Fair value of assets acquired	'	'	201
Liabilities assumed	'	'	2,322
Non-cash consideration	'	'	$6,020

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	12 Months Ended
	Dec. 31, 2012
Statements Of Cash Flows [Abstract]	'
Percentage of merger fees due to related party	3.00%

The_Company_and_Going_Concern

The Company and Going Concern	12 Months Ended
	Dec. 31, 2013
Company and Going Concern [Abstract]	'
The Company and Going Concern	'
	(NOTE A) -	The Company and Going Concern:
	On September 2, 2011, the Company completed a business combination (the “Merger”) with Pathfinder, LLC, a Massachusetts limited liability company,  in accordance with the terms of that certain Agreement and Plan of Merger, dated as of December 22, 2010 (as subsequently amended, the “Merger Agreement”).   As a result of the Merger, the Company acquired 100% of the outstanding membership interests of Pathfinder LLC in exchange for the issuance to the former members of Pathfinder, LLC of a number of shares of the Company’s common stock equal to approximately 80% of outstanding shares after issuance.  Upon the Merger, the board of directors and officers of the Company were comprised of individuals designated by Pathfinder, LLC and the business of Pathfinder, LLC became the primary business of the Company.  The Company changed its name to Pathfinder Cell Therapy, Inc. immediately prior to the Merger. Pathfinder, LLC, the Company’s wholly-owned subsidiary following the Merger, is deemed to be the “accounting acquirer,” and the transaction has been accounted for as a reverse acquisition of the Company by Pathfinder, LLC under the purchase method of accounting for business combinations.  Accordingly, the information reflected in the accompanying consolidated financial statements for periods prior to the Merger is that of Pathfinder, LLC, which began operations on November 4, 2008.
	The Company is a development stage regenerative medicine company seeking to develop novel cell-derived and related therapies for the treatment of a broad range of diseases and medical conditions characterized by organ-specific cell damage. Regarding the legacy SyntheMed business, the Company curtailed substantially all of the operations of the business and does not anticipate devoting any further resources to the business except as minimally necessary to maintain value pending a sale or other strategic transaction.
	The accompanying financial statements have been prepared on a going concern basis which contemplates continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business. For the period from November 4, 2008 (inception) through December 31, 2013, the Company has accumulated a deficit of $17,046,000, including a net loss of $1,705,000 and $2,156,000 for the years ended December 31, 2013 and 2012, has generated limited revenues and has experienced negative cash flows from operating activities. To date, the Company has relied on the proceeds raised by the issuance of convertible debt and equity to fund its operating requirements. As of December 31, 2013, the Company does not anticipate having sufficient cash on hand even when including the proceeds from subsequent borrowings in the aggregate of $305,000 through March 2014 (see Note L). The Company Does not expect to generate sufficient revenue from operations to meet its anticipated cash requirements based on its present plan of operations through December 31, 2014, without securing additional funds through the issuance of equity and/or debt. No assurance can be given that additional financing will be available to the Company on acceptable terms or at all.  In the absence of an additional cash infusion, the Company will be unable to continue as a going concern. The above conditions and events raise substantial doubt about the Company’s ability to continue as a going concern.  The financial statements do not include any adjustments relating to the recoverability and classification of the carrying amount of recorded assets or the amount and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	(NOTE B) -	Summary of Significant Accounting Policies:
	[1]	Consolidation:
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Pathfinder, LLC. All inter-company accounts and transactions have been eliminated in consolidation.
	[2]	Revenue recognition policy:
	The Company recognizes revenue when the amounts become fixed and determinable, when product is shipped to customers and receipt of payment is reasonably assured. Terms of sale are “f.o.b. shipping point” with the customer covering all costs of shipment and insurance. All sales are final with no right of return except for defective product. Product sales are generated from the SyntheMed business through sales of REPEL-CV.
	[3]	Cash and cash equivalents:
	The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions and believe any amounts in excess of insurance limitations to be at minimal risk.  Cash and cash equivalents held in these accounts are insured by the Federal Deposit Insurance Corporation up to an unlimited amount through December 31, 2012 and a maximum of $250,000, thereafter.
	[4]	Accounts Receivable:
	Accounts receivable are stated at estimated net realizable value. Management evaluates the need for an allowance for doubtful accounts based on a combination of historical experience, aging analysis and information on specific accounts. In cases where management is aware of circumstances that may impair a specific customer’s ability to meet its financial obligations, management records a specific allowance against amounts due and reduces the net recognized receivable to the amount that we believe will be collected. For all other customers, the Company maintains a reserve that considers the total receivables outstanding, historical collection rates and economic trends. Account balances are written off when collection efforts have been exhausted and the potential for recovery is considered remote.
	[5]	Intangible Assets
	Intangible assets are amortized using the straight-line method over the estimated useful life of 15 years, which is based upon management’s timelines for the typical development, approval, and marketing and life cycle of pharmaceutical drug products.
	[6]	Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets for indicators of possible impairment by comparison of the carrying amounts to future net undiscounted cash flows expected to be generated by such assets when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value or discounted estimates of future cash flows.
	During the quarter ended June 30, 2013, the Company determined that the technology licensed from the Massachusetts General Hospital (“MGH”) was no longer relevant to the development of Pathfinder’s products and terminated the MGH license agreement, impairing the entire carrying amount of this intangible asset. As a result, the Company recorded an impairment charge of $161,000 for the year ended December 31, 2013.
	[7]	Inventory:
	Inventory is stated at the lower of cost or market, as determined by the first-in, first-out method. The Company maintains an allowance for potentially slow moving and obsolete inventories. Management reviews on-hand inventory for potential slow moving and obsolete amounts and estimates the level of inventory reserve accordingly. The Company’s allowance for slow moving and obsolete inventories includes an allowance for outdated raw materials and on-hand finished goods inventory which is within six months of the expiration date. Inventory consisted of the following:
			December 31,
			2013			2012
	Raw materials		$	13,000		$	12,000
	Finished goods			-			21,000
				13,000			33,000
	Slow moving and obsolete inventories			(13,000	)		-
			$	0		$	33,000
	The production of the Company’s inventory is outsourced to third party facilities located in Ohio, Minnesota and Prince Edward Island, Canada.
	[8]	Research and development:
	All research and development activities, including any preclinical and clinical studies and product development activities, are outsourced (see Note G).  Research and development costs, representing principally new product development and manufacturing development, are charged to expense as incurred.
	[9]	Patent costs:
	Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred.
	[10]	Use of estimates:
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, on an ongoing basis. We evaluate our estimates, including those related to uncollectible receivables, inventory valuation allowance, the useful lives of intangible assets, valuation of stock-based compensation and income taxes, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	[11]	Loss per share:
	Basic loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period.  Diluted loss per share for the years ended December 31, 2013 and 2012 excludes the effect of the potential exercise or conversion of securities which would result in the issuance of incremental shares of common stock because the effect would be anti-dilutive.
	Securities and the related potential number of shares of common stock not included in the dilution computation, are as follows:
			December 31,
			2013			2012
	Options			20,402,000			20,950,000
	Warrants			6,276,000			15,906,000
				26,678,000			36,856,000
	Basic and diluted net loss per common share for the historical financial statements was computed based on the exchange ratio of shares issued in the Merger.
	[12]	Stock-based compensation:
	The Company follows FASB ASC 718 “Compensation – Stock Compensation” which requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense over the requisite service period (generally the vesting period) in the financial statements based on their fair values. For options with graded vesting, the Company values the stock option grants and recognizes compensation expense as if each vesting portion of the award was a separate award. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount of expense recognized. In addition, the realization of tax benefits in excess of amounts recognized for financial reporting purposes will be recognized in the cash flow statement as a financing activity rather than as an operating activity.
	[13]	Income taxes:
	The Company accounts for income taxes using the asset and liability method described in FASB ASC 740-10, “Income Taxes”, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance.
	[14]	Fair value of financial instruments
	The carrying amounts of cash, accounts receivables, accounts payable, accrued expenses and notes payable approximate fair value based on their short-term maturity. The carrying value of the long term payable approximates fair value, as the interest rate used to discount the payable still approximates the Company’s current borrowing rate.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2013
Intangible Assets [Abstract]	'
Intangible Assets	'
	(NOTE C) –	Intangible Assets:
	Intangible assets represent the intellectual property and other rights licensed to Pathfinder, LLC with respect to separate technologies under an agreement with each of the University of Glasgow and the Massachusetts General Hospital.  Intangible assets at each reporting date consisted of the following:
			December 31,
			2013		2012
	University of Glasgow		$	53,000	$	53,000
	MGH			-		224,000
				53,000		277,000
	Less accumulated amortization			17,000		69,000
			$	36,000	$	208,000
	The Company anticipates amortizing $3,500 per year until 2023, after which there will be an additional amortization expense through March 2024 of $1,000. The Company’s management has determined that the fair value of the University of Glasgow license exceeds the book value and thus no impairment is necessary at December 31, 2013. Amortization expense for the years ended December 31, 2013 and 2012 amounted to $11,000 and $19,000, respectively.
	[1] University of Glasgow license agreement
	In March 2009, Pathfinder, LLC entered into a worldwide exclusive license for the technology relating to Pathfinder Cells (“PCs”) from the University of Glasgow, for cash payments of $42,000 and the issuance to the University of Glasgow and the founding scientists of membership units in Pathfinder, LLC valued at $11,000. In addition, the University of Glasgow will receive royalties on sales of products making use of the PCs and related technology (see Note G[1]).
	[2]	MGH license agreement
	The Company had entered into an agreement for a worldwide exclusive license for a family of patents covering related technology from the Massachusetts General Hospital (MGH). Under the license agreement, the Company was obligated to pay a royalty ranging from 10 - 20% of all net sales of the Company’s product sales relating to the MGH licensed technology, up to a maximum amount of $15,000,000, and additional royalties of 3% of all net sales based on the technology licensed from the University of Glasgow, up to a cumulative total of $15,000,000. During the quarter ended June 30, 2013, the Company determined that the licensed technology was no longer relevant to the development of Pathfinder’s products and terminated the license agreement. As a result, the Company recorded an impairment charge of $161,000 for the year ended December 31, 2013.
	The Company has recorded a long term payable for its estimated licensing fee obligations under the MGH license agreement. The amounts recorded represent the projected future license fees payable based on the Company’s estimate of 2017 as the first year of commercial sale, discounted to the present value using the following assumptions: Net Present Value calculated as of the agreement’s effective date of April 13, 2009, using an estimated borrowing rate for the Company of 10%.  If first commercial sale is not achieved by 2017, any additional license fees incurred under the agreement will continue to be capitalized and amortized over the remaining period in the term. During the quarter ended June 30, 2013, the Company determined that the technology licensed from MGH was no longer relevant to Pathfinder’s business and terminated the MGH license agreement. As a result, the Company has reversed the long term payable in the amount of $250,000. No additional amounts are due to be paid because of the termination of the license.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2013
Notes Payable [Abstract]	'
Note Payable	'
	(NOTE D) –	Note Payable:
	[1]	Convertible Notes Payable:
	Since September 2010 and prior to the Merger, Pathfinder, LLC had been funding its operations as well as the operations of SyntheMed, Inc. with proceeds from investors, including Breisgau BioVentures SA, an owner of 52.5% of the outstanding membership interests of Pathfinder, LLC prior to the Merger, through the issuance of convertible notes payable.  The notes payable had an interest rate of 6% per annum, were due and payable on the earlier to occur of the first anniversary of issuance or the closing of the Merger and were convertible, at the election of the payee, into equity securities of the Company (then known as SyntheMed, Inc.) for the subscription price thereof in an offering by the Company conducted in connection with the Merger, which is referred to herein as the “Capital Raise”.
	At the initial closing of the Capital Raise, which occurred on September 2, 2011 immediately after the Merger, the payees elected to convert the entire outstanding principal, approximately $3,107,000 ($1,357,000 of which was held by Breisgau BioVentures SA), into the Company’s common stock sold in the Capital Raise (see Note F[2]). At December 31, 2013, the Company has included an accrual of approximately $96,000 for unpaid accrued interest, and such amount is included in Accrued Expenses in the accompanying consolidated balance sheet.
	From time to time since February 2012, the Company borrowed from investors an aggregate of $3,700,000 principal amount pursuant to promissory notes bearing interest at 6% per annum, all of which remained outstanding as of December 31, 2013. Of such amounts, $100,000 was invested by Mr. Joerg Gruber, the Company’s Chairman of the Board, and $2,035,000 was invested by Breisgau Bio Ventures SA., the Company’s principal stockholder.   Principal and interest are due and payable on the first anniversary of issuance.  None of the holders whose notes have matured, aggregating $1,965,000 in principal amount as of December 31, 2013, have requested payment.   At any time prior to completion or termination of the Capital Raise, the holder may elect to convert the principal amount of its promissory notes, and/or accrued interest thereon, into shares of the Company’s common stock in the Capital Raise at the subscription price thereof.
	[2]	Insurance Notes Payable:
	In September 2013, the Company entered into a short term financing agreement for our directors’ and officers’ liability insurance premium totaling $75,100 and payable in monthly installments including interest of $7,600. The monthly installments are due through July 2014 and carry an interest rate of 2.94% per annum.
	In March 2013, the Company entered into a short term financing agreement covering $24,400 in aggregate premiums for product liability insurance relating to the SyntheMed business.  The financed amount is payable in monthly installments each in the amount of $2,500 (including interest at 4.52% per annum) through December 2013.
	In September 2012, the Company entered into a short term financing agreement for our directors’ and officers’ liability insurance premium totaling $75,000 and payable in monthly installments including interest of $7,600. The monthly installments are due through July 2013 and carry an interest rate of 3.45% per annum.
	In March 2012, the Company entered into a short term financing agreement covering $24,400 in aggregate premiums for product liability insurance relating to the SyntheMed business.  The financed amount is payable in monthly installments each in the amount of $2,500 (including interest at 4.52% per annum) through December 2012.
	[3]	Note Payable – Clubb Capital Limited:
	In September 2011, the Company issued a note payable to Clubb Capital Limited in the principal amount of $244,000, representing the deferred portion of the commission to which Clubb Capital Limited was entitled in connection with the Capital Raise. The principal balance (together with accrued interest thereon at the rate of 6% per annum) became due and payable on demand at any time on or after December 30, 2011.

Capital_Transaction

Capital Transaction	12 Months Ended
	Dec. 31, 2013
Capital Transaction [Abstract]	'
Capital Transaction:	'
	(NOTE E) –	Capital Transaction:
	[1]	Warrants:
	As of December 31, 2013, the following warrants were outstanding to purchase up to 6,276,306 shares of the Company’s Common Stock:
			6,276,306		exercisable at $0.055 per share which expire on September 30, 2016
			6,276,306
	[2]	Options:
	As a result of the Merger each option to purchase membership interests of Pathfinder, LLC outstanding immediately prior to the Merger was assumed by the Company and converted into an option to purchase Company common stock, the number of underlying shares and exercise price per share being adjusted to reflect the Merger exchange ratio. The options were converted into options to purchase an aggregate of 14,061,000 shares with an exercise price of $0.05 per share.
	Additionally, in connection with and as contemplated by the Merger, the Company increased the number of shares authorized for issuance under its 2006 Stock Option Plan to 25,000,000.
	At December 31, 2013, the Company has one stock-based compensation plan, the 2006 Stock Option Plan, under which the Company is authorized to issue incentive stock options and non-qualified stock options to purchase up to an aggregate of 25,000,000 shares of common stock. At December 31, 2013, options to purchase 19,714,000 shares of common stock were outstanding pursuant to the 2006 plan, including 14,061,000 options that converted with the Merger, and there were 5,286,000 options available under this plan.  The exercise price is determined by the Compensation Committee of the Board of Directors at the time of the granting of an option. Options vest over a period not greater than five years, and expire no later than ten years from the date of grant.
	Additionally at December 31, 2013, options to purchase 47,000 shares of Common Stock were outstanding pursuant to the 2000 Plan, options to purchase 441,000 shares of Common Stock were outstanding pursuant to the 2001 Plan and options to purchase 200,000 shares of Common Stock issued outside of the plans are outstanding pursuant to other agreements.  These options vest over various periods and expire no later than ten years from the date of grant. Some of the outstanding options are subject to performance-based vesting.
	A summary of the status of the Company’s stock options as of December 31, 2013 and 2012, and changes during the years ended on those dates is presented below:
							Weighted			Weighted
							Average			Average		Aggregate
							Exercise			Remaining		Intrinsic
			Shares				Price			Contractual		Value
			(In Thousands)							Term
	Number of shares under option plans:
	Outstanding at January 1, 2012			23,826			$	0.19		3.6 Years
	Cancelled, expired or forfeited			2,876				0.53
	Granted			-				-		-
	Number of shares under option plans:
	Outstanding at December 31, 2012			20,950			$	0.14		3.3 Years		$	0
	Cancelled, expired or forfeited			548				0.35
	Granted			-				-
	Outstanding at December 31, 2013			20,402			$	0.13		2.4 Years		$	0
	Exercisable at December 31, 2013			20,052			$	0.13		2.3 Years
	Vested and expected to vest after December 31, 2013			20,302			$	0.13		2.3 Years		$	0
	As of December 31, 2013, there was approximately $2,000 of unrecognized stock compensation related to unvested awards (net of estimated forfeitures) expected to be recognized over the next 9 months.
	There were no options granted during the years ended December 31, 2013 and 2012, respectively.
	The Company has recorded a charge of $5,000 in general and administrative expense for the year ended December 31 2013 for the pro-rata share of the fair value of the unvested options granted during September 2011 that vest through September 2014.
	At December 31, 2013, the Company had 100,000 options outstanding which vest upon the achievement of certain performance criteria. These options have a term of 10 years from date of grant and an exercise price of $0.80.
	The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options.
	The following table summarizes information for stock options outstanding at December 31, 2013 (in thousands, except per share data):
					Options Outstanding						Options Exercisable
								Weighted-Average	Weighted-Average					Weighted-Average
	Range				Number			Remaining	Exercise Price		Number			Exercise Price
	Exercise Prices				Outstanding			Contractual Life	Per Share		Exercisable			Per Share
	$	0.05 - 0.13				17,766		2.2 years	$	0.05		17,516		$	0.05
		0.30 – 0.85				2,486		3.4 years		0.65		2,386			0.64
		1.16				150		2.7 years		1.16		150			1.16
						20,402		2.3 years	$	0.13		20,052		$	0.13

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	(NOTE F) -	Income Taxes:
	At December 31, 2013, we have approximately $40,345,000 of net operating loss carryforwards to offset future federal taxable income and approximately $574,000 of research and development tax credit carryforwards available to offset future federal income tax, subject to limitations for alternative minimum tax.  As a result of the Merger, the Company’s net operating losses and the research and development credit carryforwards will be subject to limitation, In general, the formula will be the value of the equity times the prescribed federal rate at September 30, 2011 of 3.86%.
	The Company’s net operating loss and research and development credit carryforwards expire as follows:
									Research
									and Development
		Year			Net Operating Loss				Tax Credit
		2018 - 2033			$	40,345,000			$	574,000
					$	40,345,000			$	574,000
	At December 31, 2013, the Company has net operating loss carryforwards for New Jersey State income tax purposes of approximately $16,816,000 which expire through 2028.
	The deferred tax asset, which amounted to $15,701,000 at December 31, 2013, has been offset by a valuation allowance against the entire benefit due to management's uncertainty regarding the future profitability of the Company and ability to utilize the benefit. The valuation allowance was increased by $689,000 in 2013.
	The difference between income taxes at the statutory federal income tax rate and income taxes reported in the statements of operations are attributable to the following at December 31:
			2013				2012
	Income tax benefit at the federal statutory rate		$	(580,000	)		$	(733,000	)
	Impairment of non-deductible tax goodwill			-				-
	Expired net operating losses			-				2,386,000
	Change in valuation allowance			689,000				(1,791,000	)
	Income from forgiveness of debt			-				-
	Difference in reporting basis between tax and
	accounting due to the Merger transaction			-				-
	Expired R&D credit			-				267,000
	Stock based compensation			2,000				4,000
	Company’s obligation paid by shareholder			-				-
	State and local income tax, net of effect on federal taxes			(100,000	)			(128,000	)
	Other			(11,000	)			(5,000	)
			$	0			$	0
	The deferred tax asset at December 31 consists of the following:
			2013				2012
	Net operating loss carryforward		$	14,727,000			$	14,052,000
	Research and development credit carryforward			574,000				560,000
	Other			400,000				400,000
				15,701,000				15,012,000
	Valuation allowance			(15,701,000	)			(15,012,000	)
			$	0			$	0
	Under the guidance of FASB ASC 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. As of December 31, 2013, the Company has not recorded any unrecognized tax benefits.
	The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of December 31, 2013, the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.
	By statute, tax years 2010–2013 remain open to examination by the major taxing jurisdictions to which the Company is subject to.

Research_and_License_Agreement

Research and License Agreements	12 Months Ended
	Dec. 31, 2012
Research and License Agreements [Abstract]	'
Research and License Agreements:	'
	(NOTE G) -	Research and License Agreements:
	[1]	University of Glasgow Agreements
	Pathfinder, LLC has entered into an agreement for a worldwide exclusive license for technology developed by the University of Glasgow. Under the terms of the license, Pathfinder, LLC is obligated to pay a royalty ranging from 1.5 - 3% of all sales based on the technology licensed from the University of Glasgow, up to a cumulative total of $12,000,000. The agreement terminates when the last patent expires or fifteen years from the date of the first commercial sale of a product.
	In April 2013, the parties extended the research period for an additional twelve-month period through March 2014 at a cost of approximately GBP 205,000 (approximately $338,000 based on exchange rates in effect on December 31, 2013), payable by the Company over the course of the twelve months. Under the extended agreement, the Company agreed to pay the remaining outstanding balance owed of $141,000 through March, 2014. For the year ended December 31, 2013 and 2012, the Company has incurred expense of approximately $417,000 and $691,000, respectively, under this agreement.
	[2]	MGH Agreement
	Pathfinder, LLC has entered into an agreement for a worldwide exclusive license for a family of patents covering related technology from the Massachusetts General Hospital (MGH). Under the license agreement, Pathfinder, LLC is obligated to pay a royalty ranging from 10 - 20% of all net sales of its product sales relating to the MGH licensed technology, up to a maximum amount of $15,000,000, and additional royalties of 3% of all net sales based on the technology licensed from the University of Glasgow, up to a cumulative total of $15,000,000. During the quarter ended June 30, 2013, the Company determined that the licensed technology was no longer relevant to the development of Pathfinder’s products and terminated the license agreement. As a result, the Company recorded an impairment charge of $161,000 for the year ended December 31, 2013.
	The Company has recorded a long term payable for its estimated licensing fee obligations under the MGH license agreement. The amounts recorded represent the projected future license fees payable based on the Company’s estimate of 2017 as the first year of commercial sale, discounted to the present value using the following assumptions: Net Present Value calculated as of the agreement’s effective date of April 13, 2009, using an estimated borrowing rate for the Company of 10%.  If first commercial sale is not achieved by 2017, any additional license fees incurred under the agreement will continue to be capitalized and amortized over the remaining period in the term. During the quarter ended June 30, 2013, the Company determined that the technology licensed from MGH was no longer relevant to Pathfinder’s business and terminated the MGH license agreement. As a result, the Company has reversed the long term payable in the amount of $250,000. No additional amounts are due to be paid because of the termination of the license.
	[3]	Yissum Agreement
	Effective December 1, 2011, the Company’s agreement originally entered into with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”), on June 4, 1991, as amended, was effectively terminated by the exchange of mutual releases, and the Company entered into a new agreement with Yissum relating to the polymer technology that comprised the core technology of the Company prior to the Merger in September 2011 (the “Polymer Technology”).  Pursuant to and in connection with the new agreement, (i) the Company assigned to Yissum all of its right, title and interest in and to the patents and other intellectual property relating to the Polymer Technology; (ii) Yissum granted the Company a worldwide exclusive royalty-bearing license under the applicable Polymer Technology in the following fields (A) for REPEL-CV for cardiac indications (the “REPEL Field”) and (B) for thermo-responsive polymers  to be used for or in direct connection with (1) the Company’s Pathfinder Cells, (2) drugs or biologics for the prevention or treatment of cancer or (3) post surgical adhesion prevention (the “RTG Field”); (iii) the Company agreed to commence a research program relating to the Polymer Technology for which the Company agreed to pay Yissum $40,000; (iv) $150,000 in cash which the Company deposited in escrow in September 2011 in anticipation of entering into of the new agreement with Yissum was released to Yissum and the Company issued to Yissum 1,000,000 shares of its common stock; and (v) the Company exchanged broad mutual releases with Yissum in respect of any prior claims which included any claims by Yissum for accrued and unpaid royalties or other amounts owing under the old agreement.  The Company’s rights under the new agreement are not subject to payment of minimum royalties, as they were under the prior agreement.  The Company’s rights to the Polymer Technology in the RTG Field will be subject to compliance with a development plan which the Company is to provide within an agreed upon time frame and which will be subject to Yissum’s approval.
	[4]	diZerega agreement:
	The Company is party to an agreement relating to the Polymer Technology with Gere S. diZerega, M.D. whereby the Company is obligated to pay Dr. diZerega a royalty of one percent of all net sales of covered products in any and all countries. The agreement continues until the end of fifteen years from the date of the first commercial sale of such covered product in that country. The Company incurred $1,000 in royalty expense relating to this agreement for the years ended December 31, 2013 and 2012.

Commitments_and_Other_Matters

Commitments and Other Matters	12 Months Ended
	Dec. 31, 2013
Commitments and Other Matters [Abstract]	'
Commitments and Other Matters:	'
	(NOTE H) -	Commitments and Other Matters:
	[1]	Employment agreement:
	At December 31, 2013, the Company had an employment agreement with one individual that is scheduled to expire in September 2014, subject to automatic renewal for one-year periods. Pursuant to this agreement, in case of early termination under certain circumstances, the Company’s commitment regarding cash severance benefits aggregates $28,000 at December 31, 2013 and the Company’s salary obligation for 2014 is $113,000.
	[2]	Lease commitments:
	The Company has a one year operating lease commitment for office facilities space through June 2014. The operating lease agreement is subject to renewal in annual increments at the option of the Company.  Rent is charged to operating expense on a straight-line basis over the term of lease. Rent expense under the operating lease for the year ended December 31, 2013 was $7,200.

Related_Parties

Related Parties	12 Months Ended
	Dec. 31, 2013
Related Parties [Abstract]	'
Related Parties:	'
	(NOTE I) -	Related Parties:
	Two of Pathfinder, LLC’s founding members, Dr. Richard Franklin and Mr. Joerg Gruber, have been directors of the Company (formerly SyntheMed, Inc.) since prior to entering the Merger Agreement.  Dr. Franklin, the Company’s CEO and President was SyntheMed’s sole executive officer prior to the Merger. The Company pays Dr. Franklin a monthly consulting fee of $10,000, which amount reflects a reduction, effective August, 2012, from the previous $15,000 per month consulting fee.  Mr. Gruber, the Company’s Chairman, is Chairman and a director of Clubb Capital Limited, the placement agent for the private placement.
	Between September 2010 and March 2011, Pathfinder, LLC borrowed an aggregate principal amount of $1,357,000 from Breisgau BioVentures SA, an owner of 52.5% of the outstanding membership interests of Pathfinder, LLC prior to the Merger.   Breisgau subsequently converted such principal amount into shares of the Company’s common stock in the Capital Raise. From time to time since February 2012, the Company borrowed an additional principal amount of $2,035,000 from Breisgau BioVentures SA, all of which remained outstanding as of December 31, 2013. See Note D[1].
	The Company’s core technology was originally derived from research conducted at the University of Glasgow.  The Company relies on the University of Glasgow as well as third party laboratories for its research and development activities, all of which is funded by the Company. Intellectual property resulting from activities conducted at the University of Glasgow is owned by the university and licensed to the Company under the terms of a license agreement between the university and the Company.  The university beneficially owns 9.5% of the outstanding shares of common stock of the Company. Additionally, Dr. Paul Shiels led and Dr. Wayne Davies participated in the research conducted at the university and are co-inventors of the technology derived therefrom.  Dr. Shiels is affiliated with the university and Dr. Davies was affiliated with the university at the time of the research and has since retired from that position.  Dr. Shiels assists with the Company’s research and development program through the University of Glasgow and Dr. Davies provides scientific consulting services to the Company.  Dr. Shiels and Dr. Davies beneficially own 5.7% and 3.8%, respectively, of the outstanding shares of common stock of the Company.

Retirement_Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2013
Retirement Plan [Abstract]	'
Retirement Plan:	'
	(NOTE J) -	Retirement Plan:
	The Company has a defined contribution retirement plan which was adopted by the Company (then known as SyntheMed, Inc.) in March 2007 and qualifies under section 401(k) of the Internal Revenue Code. The plan allows all employees, upon commencement of employment, to voluntarily contribute amounts not exceeding the maximum allowed under the Internal Revenue Code. The Company is obligated to make a matching contribution equal to 100% of each employee’s salary deferral contributions made at the rate of 4% of total compensation up to a maximum of $255,000. During the year ended December 31, 2013 and 2012, the Company made matching contributions to the plan in the amount of $4,500 and $4,400 respectively.

Nature_of_Business

Nature of Business	12 Months Ended
	Dec. 31, 2013
Nature of Business [Abstract]	'
Nature of Business:	'
	(NOTE K) –	Nature of Business:
	Product sales are generated from the SyntheMed business through sales of REPEL-CV.
	The following table summarizes the Company’s revenues at December 31 (in thousands):
			Years Ended December 31,
			2013		2012
			Revenues
	United States		$	-	$	13
	Brazil			8		17
	Columbia			-		15
	Italy			-		2
	Czech Republic			10		15
	Hong Kong			6		37
	Russia			27		15
	Other countries			3		-
			$	54	$	114
	All of the Company’s Long-Lived Assets are located in the United States of America.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events:	'
	(NOTE L) –	Subsequent Events:
	Subsequent to December 31, 2013, the Company borrowed an additional aggregate principal amount of $330,000, all of which was from Breisgau BioVentures SA (See Note D[1]) on the same terms as amounts borrowed from this related party during the year then ended.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Consolidation	'
	[1]           Consolidation:
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Pathfinder, LLC. All inter-company accounts and transactions have been eliminated in consolidation.
Revenue recognition policy	'
	[2]           Revenue recognition policy:
	The Company recognizes revenue when the amounts become fixed and determinable, when product is shipped to customers and receipt of payment is reasonably assured. Terms of sale are “f.o.b. shipping point” with the customer covering all costs of shipment and insurance. All sales are final with no right of return except for defective product. Product sales are generated from the SyntheMed business through sales of REPEL-CV.
Cash and cash equivalents	'
	[3]	Cash and cash equivalents:
	The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions and believe any amounts in excess of insurance limitations to be at minimal risk.  Cash and cash equivalents held in these accounts are insured by the Federal Deposit Insurance Corporation up to an unlimited amount through December 31, 2012 and a maximum of $250,000, thereafter.
Accounts Receivable	'
	[4]           Accounts Receivable:
	Accounts receivable are stated at estimated net realizable value. Management evaluates the need for an allowance for doubtful accounts based on a combination of historical experience, aging analysis and information on specific accounts. In cases where management is aware of circumstances that may impair a specific customer’s ability to meet its financial obligations, management records a specific allowance against amounts due and reduces the net recognized receivable to the amount that we believe will be collected. For all other customers, the Company maintains a reserve that considers the total receivables outstanding, historical collection rates and economic trends. Account balances are written off when collection efforts have been exhausted and the potential for recovery is considered remote.
Intangible Assets	'
	[5]	Intangible Assets
	Intangible assets are amortized using the straight-line method over the estimated useful life of 15 years, which is based upon management’s timelines for the typical development, approval, and marketing and life cycle of pharmaceutical drug products.
Impairment of Long-Lived Assets	'
	[6]	Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets for indicators of possible impairment by comparison of the carrying amounts to future net undiscounted cash flows expected to be generated by such assets when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value or discounted estimates of future cash flows.
	During the quarter ended June 30, 2013, the Company determined that the technology licensed from the Massachusetts General Hospital (“MGH”) was no longer relevant to the development of Pathfinder’s products and terminated the MGH license agreement, impairing the entire carrying amount of this intangible asset. As a result, the Company recorded an impairment charge of $161,000 for the year ended December 31, 2013.
Inventory	'
	[7]	Inventory:
	Inventory is stated at the lower of cost or market, as determined by the first-in, first-out method. The Company maintains an allowance for potentially slow moving and obsolete inventories. Management reviews on-hand inventory for potential slow moving and obsolete amounts and estimates the level of inventory reserve accordingly. The Company’s allowance for slow moving and obsolete inventories includes an allowance for outdated raw materials and on-hand finished goods inventory which is within six months of the expiration date. Inventory consisted of the following:
			December 31,
			2013			2012
	Raw materials		$	13,000		$	12,000
	Finished goods			-			21,000
				13,000			33,000
	Slow moving and obsolete inventories			(13,000	)		-
			$	0		$	33,000
	The production of the Company’s inventory is outsourced to third party facilities located in Ohio, Minnesota and Prince Edward Island, Canada.
Research and development	'
	[8]	Research and development:
	All research and development activities, including any preclinical and clinical studies and product development activities, are outsourced (see Note G).  Research and development costs, representing principally new product development and manufacturing development, are charged to expense as incurred.
Patent costs	'
	[9]         Patent costs:
	Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred.
Use of estimates	'
	[10]         Use of estimates:
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, on an ongoing basis. We evaluate our estimates, including those related to uncollectible receivables, inventory valuation allowance, the useful lives of intangible assets, valuation of stock-based compensation and income taxes, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Loss per share	'
	[11]	Loss per share:
	Basic loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period.  Diluted loss per share for the years ended December 31, 2013 and 2012 excludes the effect of the potential exercise or conversion of securities which would result in the issuance of incremental shares of common stock because the effect would be anti-dilutive.
	Securities and the related potential number of shares of common stock not included in the dilution computation, are as follows:
			December 31,
			2013			2012
	Options			20,402,000			20,950,000
	Warrants			6,276,000			15,906,000
				26,678,000			36,856,000
	Basic and diluted net loss per common share for the historical financial statements was computed based on the exchange ratio of shares issued in the Merger.
Stock-based compensation	'
	[12]         Stock-based compensation:
	The Company follows FASB ASC 718 “Compensation – Stock Compensation” which requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense over the requisite service period (generally the vesting period) in the financial statements based on their fair values. For options with graded vesting, the Company values the stock option grants and recognizes compensation expense as if each vesting portion of the award was a separate award. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount of expense recognized. In addition, the realization of tax benefits in excess of amounts recognized for financial reporting purposes will be recognized in the cash flow statement as a financing activity rather than as an operating activity.
Income taxes	'
	[13]         Income taxes:
	The Company accounts for income taxes using the asset and liability method described in FASB ASC 740-10, “Income Taxes”, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance.
Fair value of financial instruments	'
	[14]         Fair value of financial instruments
	The carrying amounts of cash, accounts receivables, accounts payable, accrued expenses and notes payable approximate fair value based on their short-term maturity. The carrying value of the long term payable approximates fair value, as the interest rate used to discount the payable still approximates the Company’s current borrowing rate.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Inventory	'
		December 31,
		2013			2012
	Raw materials	$	13,000		$	12,000
	Finished goods		-			21,000
			13,000			33,000
	Slow moving and obsolete inventories		(13,000	)		-
		$	0		$	33,000
Summary of securities and related potential Anti diluted common stock	'
		December 31,
		2013			2012
	Options		20,402,000			20,950,000
	Warrants		6,276,000			15,906,000
			26,678,000			36,856,000

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Intangible Assets [Abstract]	'
Summary of intangible assets	'
		December 31,
		2013		2012
	University of Glasgow	$	53,000	$	53,000
	MGH		-		224,000
			53,000		277,000
	Less accumulated amortization		17,000		69,000
		$	36,000	$	208,000

Capital_Transaction_Tables

Capital Transaction (Tables)	12 Months Ended
	Dec. 31, 2013
Capital Transaction [Abstract]	'
Summary of warrants	'
			6,276,306		exercisable at $0.055 per share which expire on September 30, 2016
			6,276,306
Summary of stock options activity	'
							Weighted			Weighted
							Average			Average		Aggregate
							Exercise			Remaining		Intrinsic
			Shares				Price			Contractual		Value
			(In Thousands)							Term
	Number of shares under option plans:
	Outstanding at January 1, 2012			23,826			$	0.19		3.6 Years
	Cancelled, expired or forfeited			2,876				0.53
	Granted			-				-		-
	Number of shares under option plans:
	Outstanding at December 31, 2012			20,950			$	0.14		3.3 Years		$	0
	Cancelled, expired or forfeited			548				0.35
	Granted			-				-
	Outstanding at December 31, 2013			20,402			$	0.13		2.4 Years		$	0
	Exercisable at December 31, 2013			20,052			$	0.13		2.3 Years
	Vested and expected to vest after December 31, 2013			20,302			$	0.13		2.3 Years		$	0
Summary of information for stock options outstanding	'
					Options Outstanding						Options Exercisable
								Weighted-Average	Weighted-Average					Weighted-Average
	Range				Number			Remaining	Exercise Price		Number			Exercise Price
	Exercise Prices				Outstanding			Contractual Life	Per Share		Exercisable			Per Share
	$	0.05 - 0.13				17,766		2.2 years	$	0.05		17,516		$	0.05
		0.30 – 0.85				2,486		3.4 years		0.65		2,386			0.64
		1.16				150		2.7 years		1.16		150			1.16
						20,402		2.3 years	$	0.13		20,052		$	0.13

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013										Dec. 31, 2012
Income Taxes [Abstract]	'										'
Summary of net operating loss and research and development credit carryforwards expire	'										'
									Research										Research
									and Development										and Development
		Year			Net Operating Loss				Tax Credit			Year			Net Operating Loss				Tax Credit
												2013			$	7,413,000			$	123,000
		2018 - 2033			$	40,345,000			$	574,000		2018 - 2031				31,242,000				437,000
					$	40,345,000			$	574,000					$	38,655,000			$	560,000
Summary of difference between income taxes at statutory federal income tax rate	'										'
			2013				2012						2012				2011
	Income tax benefit at the federal statutory rate		$	(580,000	)		$	(733,000	)		Income tax benefit at the federal statutory rate		$	(733,000	)		$	(3,832,000	)
	Impairment of non-deductible tax goodwill			-				-			Impairment of non-deductible tax goodwill			-				2,763,000
	Expired net operating losses			-				2,386,000			Expired net operating losses			2,386,000				1,580,000
	Change in valuation allowance			689,000				(1,791,000	)		Change in valuation allowance			(1,791,000	)			(896,000	)
	Income from forgiveness of debt			-				-			Income from forgiveness of debt			-				(457,000	)
	Difference in reporting basis between tax and										Difference in reporting basis between tax and
	accounting due to the Merger transaction			-				-			accounting due to the Merger transaction			-				332,000
	Expired R&D credit			-				267,000			Expired R&D credit			267,000				-
	Stock based compensation			2,000				4,000			Stock based compensation			4,000				287,000
	Company’s obligation paid by shareholder			-				-			Company’s obligation paid by shareholder			-				234,000
	State and local income tax, net of effect on federal taxes			(100,000	)			(128,000	)		State and local income tax, net of effect on federal taxes			(128,000	)			(101,000	)
	Other			(11,000	)			(5,000	)		Other			(5,000	)			90,000
			$	0			$	0					$	0			$	0
Summary of deferred tax asset	'										'
			2013				2012						2012				2011
	Net operating loss carryforward		$	14,727,000			$	14,052,000			Net operating loss carryforward		$	14,052,000			$	15,568,000
	Research and development credit carryforward			574,000				560,000			Research and development credit carryforward			560,000				816,000
	Other			400,000				400,000			Other			400,000				400,000
				15,701,000				15,012,000						15,012,000				16,802,000
	Valuation allowance			(15,701,000	)			(15,012,000	)		Valuation allowance			(15,012,000	)			(16,802,000	)
			$	0			$	0					$	0			$	0

Nature_of_Business_Tables

Nature of Business (Tables)	12 Months Ended
	Dec. 31, 2013
Nature of Business [Abstract]	'
Summary of company's revenues	'
		Years Ended December 31,
		2013		2012
		Revenues
	United States	$	-	$	13
	Brazil		8		17
	Columbia		-		15
	Italy		-		2
	Czech Republic		10		15
	Hong Kong		6		37
	Russia		27		15
	Other countries		3		-
		$	54	$	114

The_Company_and_Going_Concern_

The Company and Going Concern (Details) (USD $)	2 Months Ended	12 Months Ended					62 Months Ended
	Dec. 31, 2008	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2013	Sep. 02, 2011
Company and Going Concern (Textual)	'	'	'	'	'	'	'	'
Acquired outstanding membership interests (in percentage)	'	'	'	'	'	'	'	100.00%
Exchange of issuance common stock to former members (in percentage)	'	'	'	'	'	'	'	80.00%
Net loss	($32,000)	($1,705,000)	($2,156,000)	($11,270,000)	($1,294,000)	($547,000)	($17,046,000)	'
Aggregate borrowed amount	'	305,000	'	'	'	'	305,000	'
Accumulated deficit	'	($17,046,000)	($15,341,000)	'	'	'	($17,046,000)	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory	'	'
Raw materials	$13,000	$12,000
Finished goods	'	21,000
Inventory, gross	13,000	33,000
Slow moving and obsolete inventories	-13,000	'
Total inventories	'	$33,000

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive securities excluded from computation of earning per share	'	'
Antidilutive common shares	26,678,000	36,856,000
Stock Options [Member]	'	'
Antidilutive securities excluded from computation of earning per share	'	'
Antidilutive common shares	20,402,000	20,950,000
Warrant [Member]	'	'
Antidilutive securities excluded from computation of earning per share	'	'
Antidilutive common shares	6,276,000	15,906,000

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Summary Of Significant Accounting Policies (Textual)	'	'	'
Cash and cash equivalents insured through December 31, 2012	'	$250,000	'
Useful life of intangible assets	'15 years	'	'
Impairment of intangible assets	$161,000	'	$8,288,000

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Summary of intangible assets	'	'
Intangible assets	$53,000	$277,000
Less accumulated amortization	17,000	69,000
Total intangible assets	36,000	208,000
University of Glasgow [Member]	'	'
Summary of intangible assets	'	'
Intangible assets	53,000	53,000
MGH Agreement [Member]	'	'
Summary of intangible assets	'	'
Intangible assets	'	$224,000

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	12 Months Ended		62 Months Ended	1 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Mar. 31, 2009	Dec. 31, 2013	Jun. 30, 2013
				University of Glasgow [Member]	MGH Agreement [Member]	MGH Agreement [Member]
Intangible Assets (Textual)	'	'	'	'	'	'
Amortization anticipated by the company	$3,500	'	'	'	'	'
Payment for license	'	'	'	42,000	'	'
Value of membership unit in LLC	'	'	'	11,000	'	'
Amortization expense	11,000	19,000	'	'	'	'
Remaining amortization period for intangible assets	'	'Company anticipates amortizing $3,500 per year until 2023, after which there will be an additional amortization expense through March 2024 of $1,000.	'	'	'	'
Additional amortization expenses	1,000	'	'	'	'	'
Payment of royalty ranging on sales minimum (in percentage)	'	'	'	'	10.00%	'
Payment of royalty ranging on sales Maximum (in percentage)	'	'	'	'	20.00%	'
Additional payment of royalty ranging on sales (in percentage)	'	'	'	'	3.00%	'
Obligation of cumulative payment under license agreement term	'	'	'	'	15,000,000	'
Product sales	54,000	114,000	241,000	'	15,000,000	'
Impairment charges	'	'	'	'	161,000	'
Estimated rate of the Company's long term payable	'	'	'	'	10.00%	'
Long term payable	'	'	'	'	'	$250,000

Notes_Payable_Details

Notes Payable (Details) (USD $)

12 Months Ended

62 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Sep. 30, 2011

Dec. 31, 2013

Sep. 30, 2010

Dec. 31, 2013

Mar. 31, 2013

Mar. 31, 2012

Sep. 30, 2011

Sep. 30, 2010

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2011

Breisgau BioVentures SA [Member]

Breisgau BioVentures SA [Member]

Breisgau BioVentures SA [Member]

Mr. Joerg Gruber [Member]

Product liability insurance [Member]

Product liability insurance [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Promissory Notes [Member]

Financing agreement one [Member]

Financing agreement one [Member]

Note Payable [Member]

Directors' and officers' liability insurance premiums [Member]

Directors' and officers' liability insurance premiums [Member]

Notes Payable (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment ownership percentage by investor

'

'

'

'

'

52.50%

'

'

'

'

'

'

'

'

'

Investment by investor

'

'

'

'

$2,035,000

'

$100,000

'

'

'

'

'

'

'

'

Interest Rate on notes

'

'

'

'

'

6.00%

'

4.52%

4.52%

'

6.00%

6.00%

2.94%

3.45%

6.00%

Aggregate borrowed amount

305,000

'

305,000

'

'

'

100,000

'

'

'

'

3,700,000

'

'

'

Conversion of notes into common stock

'

'

3,107,000

1,357,000

'

'

'

'

'

3,107,000

'

'

'

'

'

Issuance of additional borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

244,000

Notes, monthly installment paid

'

'

'

'

'

'

'

2,500

2,500

'

'

'

'

'

'

Short term financing agreement amount covering premiums for product liability insurance

'

'

'

'

'

'

'

24,400

24,400

'

'

'

75,100

75,000

'

Notes, monthly installments paid, interest

'

'

'

'

'

'

'

'

'

'

'

'

7,600

7,600

'

Unpaid accrual Interest

$96,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Monthly installments due period

'

'

'

'

'

'

'

'Through December 2013

'Through December 2012

'

'

'

'Through July 2014

'Through July 2013

'

Capital_Transaction_Details

Capital Transaction (Details)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of warrants	'	'	'
Outstanding , Options	20,402	20,950	23,826
Warrant [Member]	'	'	'
Summary of warrants	'	'	'
Outstanding , Options	6,276,306	'	'
Expire on September 30, 2016 [Member] | Warrant [Member]	'	'	'
Summary of warrants	'	'	'
Outstanding , Options	6,276,306	'	'

Capital_Transaction_Details_1

Capital Transaction (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of stock options activity	'	'	'
Outstanding at Beginning, Shares	20,950	23,826	'
Outstanding at Beginning, Weighted Average Exercise Price	$0.14	$0.19	'
Outstanding at Beginning, Weighted Average Remaining Contractual Term	'3 years 3 months 18 days	'3 years 7 months 6 days	'
Cancelled, expired or forfeited, Shares	548	2,876	'
Cancelled, expired or forfeited, Weighted Average Exercise Price	$0.35	$0.53	'
Granted, Shares	'	'	'
Granted, Weighted Average Exercise Price	'	'	'
Outstanding at Ending, Shares	20,402	20,950	'
Outstanding at Ending, Weighted Average Exercise Price	$0.13	$0.14	'
Outstanding at Ending, Weighted Average Remaining Contractual Term	'2 years 4 months 24 days	'3 years 3 months 18 days	'
Outstanding at Ending, Aggregate Intrinsic Value	$0	$0	$0
Exercisable at December 31, 2013, Shares	20,052	'	'
Exercisable at December 31, 2013, Weighted Average Exercise Price	$0.13	'	'
Exercisable at December 31, 2013, Weighted Average Remaining Contractual Term	'2 years 3 months 18 days	'	'
Expected to vest after December 31, 2013, Shares	20,302	20,850	250,000
Expected to vest after December 31, 2013, Weighted Average Exercise Price	$0.13	$0.14	'
Expected to vest after December 31, 2013, Weighted Average Remaining Contractual Term	'2 years 3 months 18 days	'	'
Expected to vest after December 31, 2013, Aggregate Intrinsic Value	$0	$0	'

Capital_Transaction_Details_2

Capital Transaction (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary stock option	'	'	'
Outstanding , Options	20,402	20,950	23,826
Weighted-Average Remaining Contractual Life, Outstanding	'3 years 3 months 18 days	'3 years 7 months 6 days	'
Weighted-Average Exercise Price Per Share, Outstanding	$0.13	$0.14	$0.19
Options Exercisable	20,052	'	'
Weighted-Average Exercise Price Per Share, Exercisable	$0.13	'	'
0.05 - 0.13 [Member]	'	'	'
Summary stock option	'	'	'
Exercise Prices Range, Minimum	$0.05	'	'
Exercise Prices Range, Maximum	$0.13	'	'
Outstanding , Options	17,766	18,020	'
Weighted-Average Remaining Contractual Life, Outstanding	'2 years 2 months 12 days	'	'
Weighted-Average Exercise Price Per Share, Outstanding	$0.05	$0.05	'
Options Exercisable	17,516	'	'
Weighted-Average Exercise Price Per Share, Exercisable	$0.05	'	'
0.30 - 0.85 [Member]	'	'	'
Summary stock option	'	'	'
Exercise Prices Range, Minimum	$0.30	'	'
Exercise Prices Range, Maximum	$0.85	'	'
Outstanding , Options	2,486	2,780	'
Weighted-Average Remaining Contractual Life, Outstanding	'3 years 4 months 24 days	'	'
Weighted-Average Exercise Price Per Share, Outstanding	$0.65	$0.64	'
Options Exercisable	2,386	'	'
Weighted-Average Exercise Price Per Share, Exercisable	$0.64	'	'
1.16 [Member]	'	'	'
Summary stock option	'	'	'
Exercise Prices Range	$1.16	'	'
Outstanding , Options	150	150	'
Weighted-Average Remaining Contractual Life, Outstanding	'2 years 8 months 12 days	'	'
Weighted-Average Exercise Price Per Share, Outstanding	$1.16	$1.16	'
Options Exercisable	150	'	'
Weighted-Average Exercise Price Per Share, Exercisable	$1.16	'	'

Capital_Transaction_Details_Te

Capital Transaction (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Capital Transaction (Textual)	'	'	'
Common stock, shares authorized	1,000,000	1,000,000	'
Common stock, shares outstanding	667,162	667,162	'
Options converted with merger	'	'	'
Options outstanding under stock option plan	20,402	20,950	23,826
Maximum number of shares purchasable by warrants outstanding	6,276,306	'	'
Converted options	14,061,000	'	'
Purchase price of shares of acquired company, per share	$0.05	'	'
Unrecognized stock compensation related to unvested awards	$2,000	'	'
Expected period in which compensation cost recognized	'9 months	'	'
Charge recorded in general and administrative expense	$5,000	'	'
Term of options	'10 years	'	'
Exercise price of options	$0.80	'	'
Options outstanding vested upon achievement	100,000	'	'
Expire on September 30, 2016 [Member]	'	'	'
Capital Transaction (Textual)	'	'	'
Exercise price of warrants having certain expiration period	$0.06	'	'
2000 Plan [Member]	'	'	'
Capital Transaction (Textual)	'	'	'
Common stock, shares outstanding	47,000	'	'
2001 Plan [Member]	'	'	'
Capital Transaction (Textual)	'	'	'
Common stock, shares outstanding	441,000	'	'
2006 Plan [Member]	'	'	'
Capital Transaction (Textual)	'	'	'
Increase in common stock shares authorized under stock option plan	25,000,000	'	'
2006 Plan One [Member]	'	'	'
Capital Transaction (Textual)	'	'	'
Common stock, shares authorized	25,000,000	'	'
Shares Outstanding Under Stock Option Plan	19,714,000	'	'
Options converted with merger	14,061,000	'	'
Options outstanding under stock option plan	5,286,000	5,031,000	'
Period over which stock option is vested and expired	'Options vest over a period not greater than five years, and expire no later than ten years from the date of grant.	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	Dec. 31, 2013
Net Operating Loss and Research and Development Credit Carryforwards	'
Net Operating Loss	$40,345,000
Research and Development Tax Credits	574,000
2018 - 2033 [Member]	'
Net Operating Loss and Research and Development Credit Carryforwards	'
Net Operating Loss	40,345,000
Research and Development Tax Credits	$574,000

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Difference between income taxes at statutory federal income tax rate	'	'
Income tax benefit at the federal statutory rate	($580,000)	($733,000)
Impairment of non-deductible tax goodwill	'	'
Expired net operating losses	'	2,386,000
Change in valuation allowance	689,000	-1,791,000
Income from forgiveness of debt	'	'
Difference in reporting basis between tax and accounting due to the Merger transaction	'	'
Expired R&D credit	'	267,000
Stock based compensation	2,000	4,000
Company's obligation paid by shareholder	'	'
State and local income tax, net of effect on federal taxes	-100,000	-128,000
Other	-11,000	-5,000
Income Tax Benefit Continuing Operations	$0	$0

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax asset	'	'
Net operating loss carryforward	$14,727,000	$14,052,000
Research and development credit carryforward	574,000	560,000
Other	400,000	400,000
Deferred Tax Assets, Gross	15,701,000	15,012,000
Valuation allowance	-15,701,000	-15,012,000
Deferred Tax Assets, Net	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes (Textual)	'	'
Net operating loss carryforwards	$40,345,000	'
Research and Development Tax Credit	574,000	560,000
Net operating loss carryforwards State income tax	16,816,000	'
Federal tax rate	3.86%	'
Deferred Tax Assets	15,701,000	15,012,000
Valuation allowance	15,701,000	15,012,000
Operating loss carryforward expiration date	31-Dec-28	'
Increase in valuation allowance	$689,000	'

Research_and_License_Agreement1

Research and License Agreements (Details)	12 Months Ended		62 Months Ended	1 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Apr. 30, 2013	Apr. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012
	USD ($)	USD ($)	USD ($)	University of Glasgow Agreement [Member]	University of Glasgow Agreement [Member]	University of Glasgow Agreement [Member]	University of Glasgow Agreement [Member]	MGH Agreement [Member]	Yissum Agreement [Member]	Dizerega Agreement [Member]	Dizerega Agreement [Member]
				USD ($)	GBP (£)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Research and License Agreements (Textual)	'	'	'	'	'	'	'	'	'	'	'
Payment of royalty ranging on sales minimum (in percentage)	'	'	'	'	'	1.50%	'	10.00%	'	'	'
Payment of royalty ranging on sales Maximum (in percentage)	'	'	'	'	'	3.00%	'	20.00%	'	'	'
Additional payment of royalty ranging on sales (in percentage)	'	'	'	'	'	'	'	3.00%	'	'	'
Obligation of cumulative payment under license agreement term	'	'	'	'	'	$12,000,000	$12,000,000	$15,000,000	'	'	'
Number of years for agreement termination from the date of the first commercial sale of a product	'	'	'	'	'	'15 years	'	'	'	'	'
Total expenses	1,777,000	2,124,000	17,111,000	'	'	417,000	691,000	'	'	'	'
Cost of extended research period	'	'	'	338,000	205,000	141,000	'	'	'	'	'
Extended research period	'	'	'	'Twelve-month period through March 2014	'Twelve-month period through March 2014	'	'	'	'	'	'
Expenses incurred on research program	'	'	'	'	'	'	'	'	40,000	'	'
Product sales	54,000	114,000	241,000	'	'	'	'	15,000,000	'	'	'
Common stock issued to affiliates	'	'	'	'	'	'	'	'	1,000,000	'	'
Cash paid	'	'	'	'	'	'	'	'	150,000	'	'
Description of period of agreement	'	'	'	'	'	'	'	'	'	'The agreement continues until the end of fifteen years from the date of the first commercial sale of such covered product in that country.	'
Royalty expense	'	'	'	'	'	'	'	'	'	1,000	1,000
Percentage of royalty	'	'	'	'	'	'	'	'	'	1.00%	'
Impairment charge	161,000	'	8,288,000	'	'	'	'	161,000	'	'	'
Estimated borrowing rate	'	'	'	'	'	'	'	10.00%	'	'	'
Long term payable	'	$232,000	'	'	'	'	'	$250,000	'	'	'

Commitments_and_Other_Matters_

Commitments and Other Matters (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Individulas
Employment Agreement [Member]	'
Commitments and Other Matters (Textual)	'
Number of individuals	1
Agreement expiry date	30-Sep-14
Agreement renewal period	'1 year
Cash severance benefits	$28,000
Annual salary obligation	113,000
Lease commitments [Member]	'
Commitments and Other Matters (Textual)	'
Rent expense under the operating lease	$7,200
Operating lease, description	'The Company has a one year operating lease commitment for office facilities space through June 2014.

Related_Parties_Details

Related Parties (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 31, 2011
Dr. Franklin [Member]	'	'
Related Party Transactions (Textual)	'	'
Payment of consulting fee	$10,000	'
Consulting fee before reduction	15,000	'
Breisgau BioVenures SA [Member]	'	'
Related Party Transactions (Textual)	'	'
Aggregate principal amount	'	1,357,000
Investment ownership percentage by investor	'	52.50%
Additional amount borrowed	$2,035,000	'
University of Glasgow [Member]	'	'
Related Party Transactions (Textual)	'	'
Investment ownership percentage by investor	9.50%	'
Dr. Shiels [Member]	'	'
Related Party Transactions (Textual)	'	'
Investment ownership percentage by investor	5.70%	'
Dr. Davies [Member]	'	'
Related Party Transactions (Textual)	'	'
Investment ownership percentage by investor	3.80%	'

Retirement_Plan_Details

Retirement Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Retirement Plan (Textual)	'	'
Company obligated matching contribution percentage of each employee's salary	100.00%	'
Deferral contributions rate of percentage of total compensation	4.00%	'
Deferral contributions amount of total compensation	$255,000	'
Amount of matching contribution retirement plan	$4,500	$4,400

Nature_of_Business_Details

Nature of Business (Details) (USD $)	12 Months Ended		62 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenue	'	'	'
Revenues	$54	$114	$241
United States [Member]	'	'	'
Revenue	'	'	'
Revenues	'	13	'
Brazil [Member]	'	'	'
Revenue	'	'	'
Revenues	8	17	'
Colombia [Member]	'	'	'
Revenue	'	'	'
Revenues	'	15	'
Italy [Member]	'	'	'
Revenue	'	'	'
Revenues	'	2	'
Czech Republic [Member]	'	'	'
Revenue	'	'	'
Revenues	10	15	'
Hong Kong [Member]	'	'	'
Revenue	'	'	'
Revenues	6	37	'
Russia [Member]	'	'	'
Revenue	'	'	'
Revenues	27	15	'
Other Countries [Member]	'	'	'
Revenue	'	'	'
Revenues	$3	'	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	Dec. 31, 2013
Subsequent Events (Textual)	'
Aggregate borrowed amount	$305,000
Subsequent Event [Member]	'
Subsequent Events (Textual)	'
Aggregate borrowed amount	$330,000